UCB
UCB’s ambition is to transform the lives of people living with severe diseases, allowing them to live the best life they can – as free as possible from the challenges and uncertainty of disease. Leveraging scientific advances and new technologies in areas including genetics, biomarkers and human biology, their research and development activities span neurology, immunology and other areas where their expertise, innovation and ambition align with unmet needs.
Latest UCB Content
Industry Insight
Using AI To Get Medicines to Patients Faster
To find out more about AI in pharma, Technology Networks spoke with Roger Palframan, head of US Research and digital for Early Solutions at UCB.
Industry Insight
Applying AI Across All Stages of Drug Development
To learn more about the application of AI across all stages of development, from drug design to clinical trials, Technology Networks spoke with Dr. Yuan Wang, head of research analytics at UCB.
Product News
Pheno Therapeutics Announces Worldwide License From UCB to a Novel Program for Neurodegenerative Disease
Pheno Therapeutics Limited has announced that it has entered into an exclusive worldwide license agreement with UCB.
Advertisement
